FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

KI.	i ieo <i>i</i>	AIND		, MAI	NGE	CON	SIC
١٨/-	- 1-1	D 0 0	0540				

OMB APPROVAL

OIVID ALT NOVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours ner resnonse	. 05								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1(0). 36	ee Instruction	10.																			
Name and Address of Reporting Person*     SCLX Stock Acquisition JV LLC					2. Issuer Name <b>and</b> Ticker or Trading Symbol Scilex Holding Co [ SCLX ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)								
SCLA SWEK ACQUISITION JV LLC							_	-		_				Direc		1	10% O				
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 01/02/2025								Officer (give title Other (specify below) below)							
C/O SCILEX HOLDING COMPANY																					
960 SAN ANTONIO ROAD					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Inc	6. Individual or Joint/Group Filing (Check Applicable								
(Street)														Line		filed by On	e Reno	rtina Pere	on		
PALO A	LTO C	SA 9	94303												▼ Form filed by One Reporting Person Form filed by More than One Reporting						
															Perso		io triari	one rep	orung		
(City)	(:	State) (	Zip)																		
		Table	l - No	n-Deriva	tive \$	Secu	rities	Acq	uired,	, Dis	posed of	, or E	3ene	ficial	ly Own	ed					
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day					Execution Date,				es Acquired (A) o Of (D) (Instr. 3, 4 a			Securi Benefi Owned	ties Fo cially (D) d Following (I)		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount	(A (D	) or )	Price		action(s) 3 and 4)			(Instr. 4)		
Common	Stock			01/02/2	2025				J <sup>(1)(2)</sup>		5,000,00	0	D	(1)(2)	55,0	068,585		D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
			,	(e.g., pu	its, ca	alis, v	warra	ants,	optio	ns, c	onvertib	le se	curit	ties)					,		
1. Title of Derivative Security (Instr. 3)	lerivative ecurity or Exercise (nstr. 3)  Price of Derivative Security  Date (Month/Day/Year)  (Month/Day/Year)  Execution Date if any (Month/Day/Year)		Execut if any	ion Date, Transa					6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		D S (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y C F D o (I	0. Ownership orm: Direct (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amo or Num of Shar	ber									

1. Transferred pursuant to the terms of a Deferral and Consent Letter (collectively, the "Consent Letters") the Issuer and the Reporting Person entered into with each of (i) Nomis Bay Ltd and BPY Limited, (ii) Oramed Pharmaceuticals Inc. ("Oramed") and (iii) 3i, LP, respectively (collectively, the "Noteholders") for the deferral of certain amortization payments owned by the Issuer to the Noteholders. Under the terms of the Consent Letters and in consideration for such deferrals and to limit the Noteholders' right to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Consent Letters)),

2. (continued from footnote 1) the Reporting Person transferred to the Noteholders an aggregate of 5,000,000 shares of common stock, par value \$0.0001 per share of the Issuer, held by the Reporting Person, of which 2,500,000 shares were delivered to Oramed, 720,000 shares were delivered to BPY Limited, 1,280,000 shares were delivered to Nomis Bay Ltd, and 500,000 shares were delivered to 3i,

01/06/2025 /s/ Xiao Xu, Sole Manager

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.